Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2019 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-019-04360-9
Abstract: PurposeTo assess the morphological and functional outcome and stability of the “treat and extend” protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.Patients and methodsThis retrospective study included… read more here.
Keywords: age related; treatment; extend protocol; group ... See more keywords
Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Ophthalmology"
DOI: 10.1007/s10384-018-0562-0
Abstract: PurposeTo evaluate the efficacy of intravitreal aflibercept therapy using a treat-and-extend regimen on treatment-naïve pachychoroid neovasculopathy (PNV) and Type 1 neovascular age-related macular degeneration (AMD).MethodsWe retrospectively studied 42 eyes with PNV and 60 eyes with… read more here.
Keywords: pachychoroid neovasculopathy; extend regimen; polypoidal lesions; type neovascular ... See more keywords
One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Sign Up to like & getrecommendations! Published in 2020 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-020-00312-3
Abstract: To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Fifty-one eyes of treatment-naïve PCV… read more here.
Keywords: year; intravitreal aflibercept; eyes weeks; treat extend ... See more keywords
A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study)
Sign Up to like & getrecommendations! Published in 2020 at "Eye"
DOI: 10.1038/s41433-020-0901-5
Abstract: Purpose To evaluate the efficacy of intravitreal aflibercept as a second-line therapy in eyes with persistent diabetic macular oedema (DMO) despite receiving initial bevacizumab treatment. Methods A prospective multicentre study was conducted in nine academic… read more here.
Keywords: treatment; study; extend regimen; intravitreal aflibercept ... See more keywords
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-76354-1
Abstract: The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective… read more here.
Keywords: year; extend regimen; intravitreal aflibercept; treat extend ... See more keywords
Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: „Pro Re Nata versus Treat and Extend“
Sign Up to like & getrecommendations! Published in 2017 at "Klinische Monatsblatter Fur Augenheilkunde"
DOI: 10.1055/s-0042-122340
Abstract: Das Ziel dieses Artikels ist es, einen Uberblick zu geben uber verschiedene Strategien zur Verwendung von PRN- und TE T&E: treat and extend) mit intravitrealen Anti-VEGF-Medikamenten (Bevacizumab, Ranibizumab oder Aflibercept) bei Patienten mit Netzhauterkrankungen wie… read more here.
Keywords: bei; der; treat extend; prn ... See more keywords
EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Retina"
DOI: 10.1097/iae.0000000000002582
Abstract: PURPOSE To evaluate 52-week efficacy and safety of a treat-and-extend regimen of intravitreal aflibercept 2 mg on treatment-naive Type 3 neovascularization lesions. METHODS Phase IV, prospective, open-label, single-arm, multicenter trial including patients with untreated Stage… read more here.
Keywords: extend regimen; treatment; type neovascularization; treat extend ... See more keywords
LONG-TERM MORPHOLOGIC CHANGES IN MACULAR NEOVASCULARIZATION UNDER AFLIBERCEPT TREATMENT WITH A TREAT-AND-EXTEND REGIMEN
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003676
Abstract: This retrospective observational study showed that the area of macular neovascularization increased significantly after 2 years despite aflibercept treatment delivered according to a treat-and-extend regimen. The macular neovascularization area at baseline was negatively correlated with… read more here.
Keywords: extend regimen; treatment; macular neovascularization; treat extend ... See more keywords
Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study
Sign Up to like & getrecommendations! Published in 2020 at "Acta Ophthalmologica"
DOI: 10.1111/aos.14399
Abstract: To assess the noninferiority of the treat‐and‐extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in naïve patients with neovascular age‐related macular degeneration (nAMD). read more here.
Keywords: macular degeneration; age related; related macular; treat extend ... See more keywords
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Sign Up to like & getrecommendations! Published in 2021 at "Acta ophthalmologica"
DOI: 10.1111/aos.14786
Abstract: PURPOSE To assess the effect of fluid status at baseline (BL) and at the end of the loading phase (LP) of three different ranibizumab regimens: treat-and-extend (T&E), fixed bimonthly (FBM) injections and pro re nata… read more here.
Keywords: patients neovascular; bcva; fluid; study ... See more keywords
Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Ophthalmology"
DOI: 10.1136/bjophthalmol-2020-316176
Abstract: Background/aims To evaluate the long-term effects of treat-and-extend dosing of ranibizumab with and without navigated focal laser for diabetic macular oedema (DME). Methods This is a multicentre, randomised clinical trial where 150 eyes were randomised… read more here.
Keywords: laser; year; ranibizumab without; treat extend ... See more keywords